Dongguan HEC Biopharm

Dongguan HEC Biopharm is a specialized biopharmaceutical subsidiary of the HEC Group, located in the Songshan Lake High-Tech Industrial Development Zone in Dongguan, China. The company focuses on the development and large-scale production of high-quality biologics, with a primary emphasis on metabolic diseases, oncology, and infectious diseases. Its commercial portfolio includes insulin analogs such as insulin glargine and insulin aspart, which are produced in state-of-the-art GMP-compliant facilities. Beyond metabolic health, the company maintains an extensive R&D pipeline featuring monoclonal antibodies and innovative small molecules. Dongguan HEC Biopharm leverages the integrated resources of the HEC Group to advance its clinical programs through global regulatory pathways. The company is positioned as a key player in the Chinese biopharmaceutical sector, aiming to provide affordable and effective therapeutic solutions worldwide.